Extracorporeal Photopheresis (ECP)

Extracorporeal photopheresis (ECP) is covered for treatment of refractory solid organ transplant rejection, acute and chronic graft‑versus‑host disease (GVHD), late‑stage and progressive/refractory early‑stage cutaneous T‑cell lymphoma (including Sézary syndrome), and refractory bronchiolitis obliterans syndrome/chronic lung allograft dysfunction (BOS/CLAD). Coverage requires failure of standard therapies (e.g., corticosteroids/methylprednisolone for acute GVHD, cyclosporine/prednisone for chronic GVHD, standard immunosuppression for transplant rejection), diagnosis‑specific criteria (such as Sézary cell counts and post‑transplant baseline FEV1 for CLAD), and ECP is considered experimental/investigational for other or previously untreated/responding conditions; schedules vary and therapy should be discontinued if there is no clinical response.

"Organ rejection after solid organ transplant"